Today's brief highlights the expanding clinical landscape for personalized neoantigen vaccines, with multiple Phase I/II trials recruiting across solid tumors, melanoma, and endocrine cancers.trialOncLivetrialtrial
Concurrently, advances in AI-driven protein design and TCR representation learning are addressing key bottlenecks in vaccine target selection and immunogenicity prediction.arXivarXiv
Reports indicate that a personalized cancer vaccine tested in Nashville may shift treatment paradigms, highlighting growing clinical momentum for individualized immunotherapies.
Relevant work from earlier we're still surfacing — not today's news.